SCHEMBL5062533

SCHEMBL5062533

CCn1c(-c2nonc2N)nc2c(-c3cccc(N(OC(=O)C(F)(F)F)C(=O)Nc4cccc(OC)c4)c3)ncc(OCCCN)c21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 15/20 0.56
RPS6KA1 Q15418 13/20 0.56
RPS6KA5 O75582 6/20 0.56
ROCK1 Q13464 17/20 0.51
AKT2 P31751 5/20 0.43
AKT3 Q9Y243 3/20 0.43
CDC7 O00311 1/20 0.38
PLK4 O00444 1/20 0.38
AURKA O14965 1/20 0.38
DAPK3 O43293 1/20 0.38
ROCK2 O75116 1/20 0.38
PRKD3 O94806 1/20 0.38
PRKCG P05129 1/20 0.38
LCK P06239 1/20 0.38
PIM1 P11309 1/20 0.38
PRKACA P17612 1/20 0.38
RPS6KB1 P23443 1/20 0.38
CDK2 P24941 1/20 0.38
MARK3 P27448 1/20 0.38
FLT4 P35916 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5062916 0.93 AKT1 (0.56) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL5062564 0.93 AKT1 (0.56) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL5058521 0.91 AKT1 (0.58) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL5063141 0.91 AKT1 (0.54) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL5058434 0.91 AKT1 (0.57) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL5062630 0.90 AKT1 (0.62) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL5062728 0.90 AKT1 (0.54) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL5063635 0.90 AKT1 (0.56) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL5063639 0.89 AKT1 (0.61) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL5066174 0.89 ROCK1 (0.52) AKT1RPS6KA1RPS6KA5ROCK1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255143-A1 Inhibitors of Akt Activity SMITHKLINE BEECHAM CORPORATION (PA) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255143-A1 Inhibitors of Akt Activity PI4KB, PIK3CA, AKT2 AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.